希美钠联合放疗治疗鼻咽癌患者30例  

CMNa Combined with Radiation Treatment of 30 Nasopharyngeal Cancer Patients

作　　者：康红兵[1] 杜少云[1] 贺秋冬[1] 

机构地区：[1]南华大学第一附属医院放疗科,湖南衡阳421001

出　　处：《南华大学学报（医学版）》2009年第1期54-55,58,共3页Journal of Nanhua University(Medical Edition)

摘　　要：目的观察希美钠(甘氨双唑钠)联合放疗治疗鼻咽癌的近期疗效及毒副反应。方法将60例患者随机分为增敏组、普通组各30例。两组放射治疗方法、程式和剂量相同。普通组30例病例进行常规放疗治疗,增敏组30例采取希美钠联合放疗。治疗结束后观察两组疗效及不良反应。结果增敏放疗组完全缓解22例(73.3%),普通放疗组完全缓解12例(40.0%),两组疗效比较,差异有显著性(χ2=4.34,P<0.05)。两组毒副反应比较,差异无显著性。结论增敏放疗组近期疗效优于普通放疗组,且毒副反应未见明显增加。Objective To observe the near future efficacy and toxicity of the sodium glycididazo （CMNa） combined with radiation treatment of nasopharyngeal cancer. Methods 60 patients were randomly divided into enhancement group and general group 30 cases in each group, with the same radiation treatment program and the same dose. General group were treated with conventional radiation, while enhancement group were treated with CMNa combined with radiotherapy. The efficacy and side effects were observed ofter treatment. Results Twenty two cases （73.3%） in the enhancement group had complete remission, and 12 cases （40.0%） in the geneval group had complete remission. Compariing the efficacy of the two groups, the difference was significant （ Х^2 = 4.34 ）, P 〈 0.05. Comparing the toxicity, there was no significant difference. Conclusions The curative effects of the enhancement group are better than the general group with no increasing toxic - side effects.

关 键 词：希美钠 放疗增敏 毒副作用 鼻咽癌 

分 类 号：R739.63[医药卫生—肿瘤]